POLA Pharma Inc

Yokohama-shi, Japan

POLA Pharma Inc

Yokohama-shi, Japan
SEARCH FILTERS
Time filter
Source Type

Patent
Pola Pharma Inc. | Date: 2017-02-01

Provided is a technique for preparing a composition which after application forms a coating film having excellent properties although the recipe is the same. The technique is a process 1) for producing a composition of the oil-in-water emulsion preparation type which contains an optionally alkyl-modified carboxyvinyl polymer and/or a salt thereof and further contains a nonionic surfactant. The process is characterized by preparing an oil-in-water emulsion at a temperature higher than the cloud point of the nonionic surfactant, cooling the emulsion to or below the cloud point of the nonionic surfactant, then adding a carboxyvinyl polymer, and thereafter neutralizing the carboxyvinyl polymer with an alkali agent.


Patent
Pola Pharma Inc. | Date: 2015-03-27

preparing a composition, which forms a coating film having excellent properties after application though the formulation is the same characterized in that 1) a method of producing a composition of an oil-in-water emulsifier type containing a carboxyvinyl polymer optionally alkyl-modified and/or a salt thereof and a nonionic surfactant, wherein an oil-in-water emulsion is prepared at a temperature higher than the cloud point of the nonionic surfactant, the emulsion is cooled to a temperature not higher than the cloud point of the nonionic surfactant, then, a carboxyvinyl polymer is added, and thereafter, the carboxyvinyl polymer is neutralized with an alkaline agent.


Patent
Nihon Nohyaku Co. and Pola Pharma Inc. | Date: 2016-11-03

A pharmaceutical composition for external use, including: i) luliconazole represented by the following structural formula (1) and/or a salt thereof; and ii) N-methyl-2-pyrrolidone. ()-(E)-[(4R)-(2,4-dichlorophenyl)-1,3-dithiolan-2-iliden]-1-imidazolyl acetonitrile


Patent
Pola Pharma Inc. and Nihon Nohyaku Co. | Date: 2016-08-25

Disclosed is an antifungal agent for external use, which is characterized by containing a compound represented by the general formula (1), 50 to 95 mass % of an alcohol such as ethanol, 0.1 to 35 mass % of water or the like, and 0.01 to 5 mass % of a cellulose thickening agent. X is a halogen or H.


An object is to provide a crystal having a new crystal habit of luliconazole and expand the possibility of application to pharmaceuticals. Disclosed is a crystal of luliconazole having such a crystal habit that (020) plane is a specific crystal growth surface.


Patent
Pola Pharma Inc. and Nihon Nohyaku Co. | Date: 2014-11-14

The present invention aims to provide a pharmaceutical composition for pneumonia associated at least with a Fusarium fungus as a causative microorganism. Provided is a pharmaceutical composition for pneumonia associated at least with a Fusarium fungus as a causative microorganism, which pharmaceutical composition includes as an effective component a compound represented by the General Formula (1) below: (wherein R represents a halogen atom or hydrogen atom, and X represents a halogen atom).


Patent
Pola Pharma Inc. and Nihon Nohyaku Co. | Date: 2015-01-08

Disclosed is a method of evaluating stability of a pharmaceutical preparation containing luliconazole. The method includes measuring an amount of production of an SE form of luliconazole represented by following formula (2), an amount of production of a Z form of luliconazole represented by following formula (3) and an amount of production of an amide form of luliconazole represented by following formula (1) after storage under a severe condition or an accelerated condition, and judging that the stability of the pharmaceutical preparation is high if each of the amount of production of the SE form, the amount of production of the Z form and the amount of production of the amide form is not more than 5% by weight with respect to a compounded amount of luliconazole.


Provided is a method for identifying and suppressing abnormal growth of fibroblasts at an early stage. Provided is a method for identifying the growth state of fibroblasts using as an index the level of expression of ETFB (electron transfer flavoprotein beta subunit), comprising: judging, in cases where the level of expression of ETFB is high, that there is a high probability that fibroblasts are abnormally growing; and judging, in cases where the level of expression of ETFB is low, that there is a high probability that fibroblasts are normally growing. Further, by inhibition of ETFB, abnormal growth of fibroblasts can be suppressed.


Patent
Pola Pharma Inc. | Date: 2016-05-18

A means for increasing the amount of an effective component retained in a composition for a pump foamer is provided. The present invention provides a composition for external use containing: 1) an N-alkyl-2-pyrrolidone and/or a diester carbonate; and 2) a surfactant; which composition is in a foam state upon use.


Patent
Pola Pharma Inc. | Date: 2014-07-10

A means for increasing the amount of an effective component retained in a composition for a pump foamer is provided. The present invention provides a composition for external use containing: 1) an N-alkyl-2-pyrrolidone and/or a diester carbonate; and 2) a surfactant; which composition is in a foam state upon use.

Loading POLA Pharma Inc collaborators
Loading POLA Pharma Inc collaborators